CLOVER HEALTH INVESTMENTS, CORP. /DE(CLOV)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,184 of 2,879 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CLOV Stock Analysis & AI Quality Score
AI stock analysis and institutional research for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLOV at 55.0/100 on a 32-signal composite quality model, placing it at rank #1,184 of 2,879 stocks — the top half of the AI-ranked universe. CLOV scores in the top quartile across revenue growth (87.4). Areas of concern include institutional flow (28.0) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CLOVER HEALTH INVESTMENTS, CORP. /DE reports quarterly revenue of $749.2M, net income of $27.3M, free cash flow of $107.0M. Top institutional holders of CLOV by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. CLOV trades on the Nasdaq exchange and files with the SEC under CIK 1801170. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLOV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CLOVER HEALTH INVESTMENTS, CORP. /DE directly from SEC EDGAR. CLOVER HEALTH INVESTMENTS, CORP. /DE's 13F Pro composite quality score has ranged between 31 and 55 since 2024, currently 55.0 — an improving long-term trajectory across 15 quarterly and live scoring snapshots.
Revenue
Q1 2026
$749.2M
Net Income
Q1 2026
$27.3M
Free Cash Flow
Q1 2026
$107.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+40.3% YoYNet Income
-98.9% YoYOperating Income
-87.0% YoYEPS (Diluted)
Total Assets
-6.8% YoYTotal Debt
Op. Cash Flow
-292.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $1.92B +40.3% | $1.37B +8.8% | $1.26B +15.0% | $1.10B -25.5% | $1.47B +218.4% | $462.3M |
| Net Income | $-85.5M -98.9% | $-43.0M +79.8% | $-213.4M +37.2% | $-339.6M +42.2% | $-587.8M -61.6% | $-363.7M |
| Operating Income | $-85.5M -87.0% | $-45.7M +77.7% | $-205.3M +28.4% | $-286.7M +55.0% | $-637.0M -247.7% | $-183.2M |
| EPS (Diluted) | — | — | $-0.44 +38.0% | $-0.71 +50.0% | $-1.42 +65.7% | $-4.14 |
| Total Assets | $541.0M -6.8% | $580.7M +1.8% | $570.7M -29.4% | $808.6M -15.0% | $950.8M +947425.6% | $100.3K |
| Total Debt | — | — | — | $0.00 -100.0% | $20.0M | — |
| Operating Cash Flow | $-66.9M -292.1% | $34.8M +124.1% | $-144.7M +29.1% | $-203.9M +27.8% | $-282.3M -76.6% | $-159.9M |
Get alerted when CLOV's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CLOVER HEALTH INVESTMENTS, CORP. /DE including:
Top Institutional Holders of CLOV
BlackRock, Inc.
$56.0M31,840,512 shVANGUARD CAPITAL MANAGEMENT LLC
$29.9M16,982,073 shGEODE CAPITAL MANAGEMENT, LLC
$17.7M10,055,510 shSTATE STREET CORP
$16.8M9,559,889 shCHARLES SCHWAB INVESTMENT MANAGEMENT INC
$9.3M5,300,475 shPNC FINANCIAL SERVICES GROUP, INC.
$6.6M3,764,034 shVANGUARD PORTFOLIO MANAGEMENT LLC
$6.5M3,696,437 shDIMENSIONAL FUND ADVISORS LP
$6.0M3,417,866 shRENAISSANCE TECHNOLOGIES LLC
$6.0M3,401,541 shNORTHERN TRUST CORP
$5.8M3,306,575 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $56.0M | 31,840,512 |
| VANGUARD CAPITAL MANAGEMENT LLC | $29.9M | 16,982,073 |
| GEODE CAPITAL MANAGEMENT, LLC | $17.7M | 10,055,510 |
| STATE STREET CORP | $16.8M | 9,559,889 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9.3M | 5,300,475 |
| PNC FINANCIAL SERVICES GROUP, INC. | $6.6M | 3,764,034 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6.5M | 3,696,437 |
| DIMENSIONAL FUND ADVISORS LP | $6.0M | 3,417,866 |
| RENAISSANCE TECHNOLOGIES LLC | $6.0M | 3,401,541 |
| NORTHERN TRUST CORP | $5.8M | 3,306,575 |
More Healthcare Companies
View all Healthcare →Put CLOV on your watchlist
Track score changes the day CLOVER HEALTH INVESTMENTS, CORP. /DE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CLOV a good stock to buy?
13F Pro's AI-powered analysis of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLOV are available on the CLOV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CLOV?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLOV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CLOVER HEALTH INVESTMENTS, CORP. /DE's investment landscape.